É. Antoine

发表

Management of Anemia in Advanced Breast and Lung Cancer Patients in Daily Practice: Results of a French Survey

I. Ray-Coquard, F. Scotté, J. Morère, 2012, Advances in Therapy.

Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.

M. Weil, C. Borel, C. Soubrane, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Docetaxel. A review of its role in breast cancer treatment.

M. Weil, G. Auclerc, D. Khayat, 1997, American journal of clinical oncology.

The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.

D. Khayat, G. Bastian, D. Nizri, 2001, Oncology.

Taxol in the Management of Cancers of the Breast and the Ovary

D. Khayat, D. Coeffic, É. Antoine, 2000, Cancer investigation.

Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy

D. Khayat, M. Gil-delgado, R. Mouawad, 2002, Melanoma research.

A comparative study of Fas and Fas‐ligand expression during melanoma progression

D. Khayat, M. Gil-delgado, R. Mouawad, 2000, The British journal of dermatology.

Effect of endogenous interleukin-6 on Fas (APO-1/CD95) receptor expression in advanced melanoma patients.

D. Khayat, R. Mouawad, C. Soubrane, 2000, Cytokines, cellular & molecular therapy.

European School of Oncology European consensus on the use of granulocyte colony-stimulating factor: the example of breast cancer

D. Khayat, É. Antoine, 1996, Cancer Chemotherapy and Pharmacology.

Dose intensification and breast cancer: current results and future perspectives.

D. Khayat, É. Antoine, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Ectopic pregnancy in a breast cancer patient receiving trastuzumab.

O. Mir, F. Goldwasser, E. Sauvanet, 2008, Reproductive toxicology.

European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.

D. Khayat, G. Bastian, M. Gil-delgado, 1998, Oncology.

Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience.

C. Borel, G. Auclerc, L. Thill, 1993, European journal of cancer.

Phase I‐II Study of Irinotecan in Combination With Mitomycin C in Patients With Advanced Gastrointestinal Cancer

D. Khayat, H. Bismuth, F. Guinet, 2001, American journal of clinical oncology.

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.

C. Borel, L. Thill, D. Khayat, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients

T. Petit, C. Borel, G. Auclerc, 1995, Melanoma research.

Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma.

G. Auclerc, D. Khayat, N. Mortier, 1997, The cancer journal from Scientific American.

Management of advanced prostate cancer.

G. Auclerc, D. Khayat, F. Cajfinger, 2000, The oncologist.

[Management of anaemia in patient with cancer: results of the F-ACT study (French Anaemia Cancer Treatment)].

F. Morschhauser, E. Guardiola, É. Antoine, 2007, Bulletin du cancer.

Docetaxel in combination chemotherapy for metastatic breast cancer.

D. Khayat, É. Antoine, 1997, Seminars in oncology.

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

A. Vincent-Salomon, T. Delozier, M. Namer, 2010, The oncologist.

Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.

D. Khayat, S. Monfardini, P. Chollet, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study.

M. Namer, M. Ozsahin, H. Marsiglia, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintaining professional activity during breast cancer treatment.

N. Dohollou, H. Naman, A. Lortholary, 2016, European journal of cancer care.

197 Interim results of a sequential administration of docetaxel (taxotere®) followed by Cisplatin-vindesine in chemotherapy naive patients with locally advanced or metastatic non small cell lung cancer (NSCLC)

D. Khayat, J. Bérille, J. Derenne, 1997 .

Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment

N. Texier, F. Scotté, É. Antoine, 2021, BMJ supportive & palliative care.

Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy?

D. Khayat, M. Gil-delgado, R. Mouawad, 1999, Melanoma research.

ONCODOC: a successful experiment of computer-supported guideline development and implementation in the treatment of breast cancer

Jacques Bouaud, Brigitte Séroussi, Éric-Charles Antoine, 2001, Artif. Intell. Medicine.

A Before-After Study Using OncoDoc, a Guideline-Based Decision Support-System on Breast Cancer Management: Impact upon Physician Prescribing Behaviour

Jacques Bouaud, Brigitte Séroussi, Éric-Charles Antoine, 2001, MedInfo.

Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.

G. Auclerc, C. Soubrane, D. Khayat, 1996, Seminars in Oncology.

A Phase II Study of Tamoxifen Combined with Cisplatin‐Interleukin 2 and Alpha‐Interferon in Metastatic Melanoma

C. Borel, G. Auclerc, C. Soubrane, 1995, American journal of clinical oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma.

G. Auclerc, C. Soubrane, D. Khayat, 1997, Seminars in oncology.